A股異動 | 申昊科技漲5% 與浙江交投軌道交通科技簽署合作協議
格隆匯1月6日丨申昊科技(300853.SZ)現漲5.85%,報42.13元,總市值61.9億元。申昊科技1月5日發佈公吿,公司與浙江交投軌道交通科技有限公司於2022年1月1日簽署了《合作協議》,雙方同意開展合作,加速推進鐵路,軌道交通、高速公路在機器人、人工智能和大數據等新興技術領域合作,通過資源共享,聯合進行市場拓展、技術研發,建立全面穩定的合作伙伴關係,從而促進共同發展。另外,申昊科技於同日公吿,根據相關通知,公司順利通過了浙江省科學技術廳的審核、評審以及公示等環節,被認定為“2022年度省級重點實驗室”,實驗室名稱為“浙江省智能運維機器人重點實驗室”(共建單位:浙江大學)。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.